Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib in Langerhans Cell Histiocytosis
NCT01395004Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afuresertib in Langerhans cell histiocytosis (LCH), sponsored by GSK. Primary endpoints: Objective disease response at 6 months, Proportion of subjects experiencing greater than or equal to grade 3 neutropenia and 2 more. Started Nov 2011; status: completed.
02
Drugs
afuresertib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT01395004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395004.